Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tepnel Adds Invader Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tepnel Adds Invader Technology

Enhances Molecular Genetic Services portfolio

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Tepnel Pharma Services has added to its Molecular Genetic Services portfolio with Hologic’s proprietary Invader and Invader Plus technology. The new technology enables Tepnel to offer customers a more cost effective and high throughput genotyping and copy number variation (CNV) service, according to the company. Tepnel is a division of Hologic.

The Invader chemistry platform is an isothermal, DNA-probe based system used in disease detection, genotyping and CNV assays. Invader Plus couples target amplification with specificity. Invader chemistry is currently used in multiple FDA-approved and CE-marked products and is used by laboratories worldwide for their clinical diagnostic, research and high throughput genotyping needs.

Dr. Bob Holt, Molecular Genetic Services manager, Tepnel Pharma Services, commented, “We are excited to offer Invader as part of our Molecular Genetic Service portfolio. The highly versatile nature of the technology will allow Tepnel to expand into the AgBio space and extend our capabilities in biomarker discovery, clinical assay development, and companion diagnostic development in support of preclinical, clinical and personalized medicine studies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics